Catalyst Biosciences Inc (NASDAQ:CBIO) shares shot up 6.9% during mid-day trading on Tuesday . The company traded as high as $11.88 and last traded at $11.60. 1,595,911 shares were traded during trading, an increase of 254% from the average session volume of 451,115 shares. The stock had previously closed at $10.85.
A number of analysts have recently weighed in on CBIO shares. B. Riley downgraded shares of Catalyst Biosciences from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $44.00 to $12.50 in a research report on Thursday, June 21st. Chardan Capital reaffirmed a “buy” rating and issued a $35.00 target price on shares of Catalyst Biosciences in a research report on Tuesday, June 19th. BidaskClub raised shares of Catalyst Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, June 19th. ValuEngine raised shares of Catalyst Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, June 1st. Finally, Zacks Investment Research downgraded shares of Catalyst Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, May 30th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $25.83.
The stock has a market capitalization of $125.56 million, a price-to-earnings ratio of -1.56 and a beta of 2.39.
Catalyst Biosciences (NASDAQ:CBIO) last released its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.15) by $0.59. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.23 million. Catalyst Biosciences had a negative net margin of 2,983.40% and a negative return on equity of 39.27%. equities analysts expect that Catalyst Biosciences Inc will post -2.89 EPS for the current fiscal year.
A number of hedge funds have recently made changes to their positions in the stock. EAM Global Investors LLC purchased a new stake in Catalyst Biosciences during the 1st quarter valued at about $644,000. Iguana Healthcare Management LLC bought a new position in Catalyst Biosciences during the 1st quarter valued at about $2,580,000. Millennium Management LLC bought a new position in Catalyst Biosciences during the 1st quarter valued at about $1,620,000. Nexthera Capital LP lifted its stake in Catalyst Biosciences by 73.1% during the 1st quarter. Nexthera Capital LP now owns 538,624 shares of the biopharmaceutical company’s stock valued at $13,896,000 after acquiring an additional 227,449 shares during the period. Finally, Sio Capital Management LLC lifted its stake in Catalyst Biosciences by 468.5% during the 1st quarter. Sio Capital Management LLC now owns 1,149,989 shares of the biopharmaceutical company’s stock valued at $29,670,000 after acquiring an additional 947,708 shares during the period. 76.76% of the stock is currently owned by institutional investors.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.